SMC°Ltd.





Primary and Secondary Packaging - Innovation and Latest Developments

Asmita Khanolkar, Sept 14, 2023

SMC[®]Ltd.

SMC°Ltd.



Global Manufacturer of Drug Delivery
Devices (Injection, Autoinjectors,
On-body devices, Inhalation & Transdermal)





Specializes in Design, Development and Industrialisation of SC/IM patient-centric autoinjectors





Pharmaceutical Services,
Fill/Finish, Stability, Clinical &
Commercial batches

"End-to-End Services"







Primary & Secondary Packaging-Innovation and Latest Trends

Table of contents

- 1. Current Pharmaceutical Landscape
- 2. Novel Therapy Trends
- 3. Parenterals New Requirements
- 4. Paradigm Shift in Packaging Model
- 5. Packaging Strategies

Innovation

Integration

Digitalization

Sustainability

6. Primary and Secondary Packaging Trends







The Current Landscape

Research Discovery Pre-Clinical Phase I Phase II Phase III Approval Commercial

Drug Discovery

- Rapid evaluation of novel drugs and approaches
- Novel Therapies Bio therapeutics, Targeted therapies, IV to SC, LAI
- Unknowns Dose/Route
- New Regulatory Pathways
- Urgency, Speed to clinic

Clinical Evaluation

- Decentralization Trends
- Clinical trials at home
- Non-traditional settings
- Self Administration
- Isolation, Remote Care
- Remote training
- Trial Delays, Recruitment difficulty, loss of patients

Manufacturing & Launch


- Rapid Capacity
- Supply Shortage, Lead times
- Smaller Volumes
- Specialized Processes
- Iterative Scale-Up Strategies
- Single-use technology
- Adaptive Manufacturing
- Automation & Robotics







Pharmaceutical Packaging Model



Drug Product Development & Therapy Optimization

Drug Product Development & Primary Packaging

- Primary Drug Container materials
- Vials, Syringes, Cartridges, Custom PDC
- High Pressure Container Closure Systems
- Ready to Fill Systems
- Sterile Fill-Finish

Device Assembly & Secondary Packaging

- Drug Handling & Co-packing
- Delivery Optimization
- Device Development & Assembly
- Automation & In-line testing
- Cartons, Blister pack
- IFU, Labeling, Branding

Final and Tertiary Packaging

- Bulk Packing
- Kitting
- Serialization, Aggregation, Digitization
- Distribution, Track and Trace







Parenteral Packaging Strategies



®New Container Closure Systems

ODeveloping Glass Alternatives

OIntuitive Device Design

©New Packaging Materials

©Cleaner Packaging



@Pharma 4.0

©Automation

©Adaptive Manufacturing

©Additive Manufacturing, 3D Printing

© Emerging and Disruptive Technologies



©Simulation and 3D Modelling

©RFID tags, Counterfeit

©Temp, Humidity, Light Sensing

©Real Time Monitoring

© Labelling, Serialization, QR Codes



©Biodegradable Materials

©Recycling

@Re-use

Minimizing Waste in Production

OImproving Efficiencies







Patient- Centric Device Development

Research potential user groups and use environments Identify key user needs to be addressed

Early-stage fieldwork

Key functional and user requirements defined

Develop device design path

Identify Device Path

Turn inputs into early-stage concepts and identify what works for patients Comparative preference testing for multiple options to be evaluated

> Formative Evaluation


HF and device development teams work together to ensure functional and user needs are met Feedback loop between formative evaluation and device development until device is ready for summative

Iterate and Refine

Assess identified critical tasks

HE validation to prove that the device is safe and effective for use

Summative Evaluation









Sterility & Stability in Process and Use



Formulation

• Bulk vessels per capacity, Re-usable versus single-use

• Impeller options for homogeneity and sensitive products

• Special requirements shelf, filtration, inert gas head space

Filling process

• Filling process development for new formulations

• Standard versus Custom PDC development

• Stopper position control for downstream assembly

Container Closure

• Closure system selection for custom device and process

Validation of closures including stability/ shelf life

• Inspection; CCI method development

Sterilization

• Sterilization strategy development

• Bioburden and Sterility Assurance Planning

• Control of primary hermetic closure

Device Assembly

•Assembly steps must not compromise container closures

• Drug paths must be sterilizable and maintain sterility

•Secondary packaging developed to align with sterility concept

Sterile seals identified and validated

Stability/ shelf life determined

Secondary packaging







Supply Chain - Speed to Clinic















Drug Formulation & Scale-Up

Device Design & Development

Fill-Finish Process Development

Clinical Trial Manufacturing

Commercial Manufacturing

Storage & Logistics

Global Distribution

Clinical Supply Chain

Commercial Supply Chain

- Innovative Primary Container Closure Systems and Secondary Device Packaging Designs
- Small Batch, Flexible, Adaptive Manufacturing for speed to clinic
- Broad Experience providing solutions for challenging formulations
- Specialized equipment and infrastructure to optimize fill-finish and packaging
- Innovation through single-use systems, automation, non-contact processing, robotic inspection and container closure integrity testing
- Provide modular platforms for early engagement with delivery packaging systems for successful personalized clinical trials







THANK YOU!

asmita.khanolkar@smcltd.com

www.smcltd.com

www.ovalmedical.com

www.cambridgepharma.com





